Floatz logo

[18F]F-RESCA-RCCB6

Renal Clear Cell Carcinoma

RenJi HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Renal Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Everolimus
Peking University First Hospital
Phase 2BB
Axitinib
University of California, San Francisco
Phase 3B
Nivolumab
Exelixis
Phase 2B
gw786034
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2B
MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN
Oxford BioMedica
Phase 3B

View all 39 →

Same molecule, other indications

[18F]F-RESCA-RCCB6 is also rated in:

renal cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
nasopharyngeal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →